This activity has been designed to meet the educational needs of hepatologists, gastroenterologists, hospitalists/intensive care specialists, nephrologists, nurse practitioners (NPs), physician assistants (PAs), nurses (RNs) and other healthcare professionals involved in the care of patients with Hepatorenal syndrome (HRS).
Upon completion of this educational activity, participants should be able to:
Define the types of HRS, its prevalence rates, and proposed pathophysiology
Discuss the International Club of Ascites (ICA) criteria for the diagnosis and management of acute kidney injury (AKI) in cirrhosis and apply these criteria in clinical practice
Review the clinical signs of HRS and recognize the differing treatment goals in HRS (i.e. long-term treatment improvement of liver function vs. short term improvement of kidney function)
Recognize the need for approved therapies for HRS in the U.S. and apply recommended treatment strategies to clinical practice in the absence of these therapies
Identify new advancements in the treatment of HRS
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and the Chronic Liver Disease Foundation Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.
Purdue University College of Pharmacy designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
All faculty, staff and reviewers involved in the planning, review or presentation of continuing education activities provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity.
All additional planning committee members, staff and reviewers of the Chronic Liver Disease Foundation and Purdue University College of Pharmacy have no relationships to disclose.
This program is supported by an educational grant from Mallinckrodt Pharmaceuticals.